Allos Efaproxyn "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allos' radiation sensitizer Efaproxyn (efaproxiral, RSR-13) is "approvable" May 27 for treatment of brain metastases originating from breast cancer. Approval is contingent upon successful completion of the Phase III ENRICH study. "If the study shows effectiveness in this population (increased survival) using the pre-specified analysis, and the study is otherwise satisfactory, we believe it would, together with the subset result in RT-009, support approval," FDA's letter states. Allos limited the RSR-13 filing to breast cancer after the RT-009 trial showed significance in a subset of patients with breast cancer, but not in the overall population (1Pharmaceutical Approvals Monthly Dec. 1, 2003, p. 6). Allos announced European submission of efaproxiral June 4 for the same indication, under the centralized procedure...
You may also be interested in...
Schering-Plough Temodar Gets Priority Review For First-Line Glioma
Schering-Plough’s brain tumor therapy Temodar will receive a priority review for first-line treatment of newly diagnosed, high-grade gliomas, the firm announced Oct. 29.
Allos Limits RSR13 Brain Metastases NDA To Breast Cancer; User Fee In June
Allos expects its radiation sensitizer RSR13 (efaproxiral) to receive a priority review for the treatment of brain metastases from breast cancer, placing the user fee goal date in June.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.